Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Rheumatoid Arthritis (RA)"

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

Canada & E.U. Approve Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  January 28, 2020

Upadacitinib will soon be available to treat patients with moderate to severe rheumatoid arthritis in Canada and the E.U…

Non-Pharmacological Interventions & Management of RA-Related Fatigue

Lara C. Pullen, PhD  |  January 13, 2020

Often, rheumatoid arthritis (RA) patients struggle with fatigue, and the cause of the fatigue remains unclear. Past research suggests RA-related fatigue may be moderately improved by physical activity. A recent narrative review supports these prior findings, noting that patients also benefit moderately from psychosocial interventions…

RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors

Lara C. Pullen, PhD  |  January 8, 2020

In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…

Antibiotic Use Linked to Higher Risk for RA

Carina Stanton  |  November 18, 2019

New research finds patients previously treated with antibiotics, antifungals and antivirals may be more likely to develop rheumatoid arthritis than patients who have not received these treatments…

Physical Activity Reduces Risk of Rheumatoid Arthritis

Lara C. Pullen, PhD  |  October 31, 2019

A recent study has taken a more detailed look at the relationship between physical activity and the risk of developing rheumatoid arthritis (RA). Researchers found the more patients exercised weekly the lower their overall risk, specifically brisk and very brisk walking paces, along with longer cumulative average walking hours weekly were associated with a reduced risk for RA…

New Options for Treatment-Resistant RA

Carina Stanton  |  October 14, 2019

Two JAK inhibitors, one recently approved by the FDA, have shown improvements in patients with active RA for whom other therapies have proved ineffective…

Abx464 Enters Phase 2 Clinical Trials for RA in Europe

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2019

In Europe, researchers are evaluating the safety, tolerability and efficacy of ABX464 in rheumatoid arthritis patients…

Catch Your Breath: Insights into ILD in RA Patients

Jason Liebowitz, MD, FACR  |  September 12, 2019

Detecting interstitial lung disease in RA patients can be challenging. But evaluating risk factors and the use of imaging can help clinicians identify and manage this condition in patients…

FDA Approves Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  September 2, 2019

Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences